Indications -- Hepatitis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Hepatitis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (82)	10/18/2004 12:11:01 PM
From: tuck	of 312

>>Valeant’s Potential Hepatitis C Blockbuster 10.18.04, 11:30 AM ET Merrill Lynch initiated coverage of Valeant Pharmaceuticals (nyse: VRX - news - people ) with a "buy" rating and said the specialty pharmaceutical company has a "potential blockbuster" in its hepatitis C drug, Viramidine, currently in Phase III trials. "This drug could become the 'gold standard' treatment and generate more than $1 billion in annual sales," Merrill Lynch said. The research firm placed a $32 target price for the stock and said Phase II data indicates Viramidine has a similar efficacy to Ribavirin, which it calls "the current gold standard," but with lower rates of anemia. Ribavirin, originally developed by Schering Plough (nyse: SGP - news - people ), is currently marketed by Teva Pharmaceutical Industries (nasdaq: TEVA - news - people ). Merrill Lynch expects Valeant's Phase III trials to be completed by late 2006 and a mid-2007 launch. The firm projects 2004 and 2005 earnings-per-share estimates at 6 cents and 23 cents, respectively. << Courtesy of Forbes.com Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next